
This book summarizes the present knowledge of oxidative stress in anti-cancer drug-induced cardiotoxicity and covers cell molecular mechanisms, prevention and treatment strategies, drug research, and population experiments. Racial and gender disparities in anticancer therapy-related cardiotoxicity are also covered. Book chapters provide current and timely review of hypothesis-driven research, case studies, and review articles. As such, this book serves as a source of knowledge and guidance for research, clinical prevention, and treatment of cardiotoxic anticancer drugs.
Furthermore, this book is essential for students, cardiologists, cardio-oncologists, and heart failure researchers.
Inhaltsverzeichnis
Part 1. Epidemiology & Cardiac Signaling. - 1. Risk Factors Associated with Anthracycline Induced Cardiac Dysfunction. - 2. Multilevel Drivers of Disparities in Cardio-oncology. - 3. Cardiotoxicity, Cancer Therapies, and Cardiac Cell Signaling. - 4. Phytochemicals in Cardiotoxicity and Cardioprotection. - Part II. Current Trends in Detection and Management. - 5. Detection, Prevention, & Management of Anthracycline-induced Cardiotoxicity. - 6. Pharmacotherapies in Prevention of Myocardial Oxidative Stress. - 7. Optimizing Cardiovascular Safety: Cardiotoxicity Prevention in Tyrosine Kinase Inhibitor, Monoclonal Antibody, Proteosome Inhibitor, and 5-Fluorouracil Anticancer Therapies. - 8. The Future of Cardio-oncology.
Es wurden noch keine Bewertungen abgegeben. Schreiben Sie die erste Bewertung zu "Myocardial Oxidative Stress in Anti-Cancer Therapies" und helfen Sie damit anderen bei der Kaufentscheidung.